3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
17
Melanoma
3
Glioma
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Diffuse Intrinsic Pontine Glioma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Rhabdoid Tumor
1
Osteitis Deformans
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Mesothelioma
1
Medulloblastoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Familial ependymoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Cystadenocarcinoma, Serous
1
Carcinoma, Hepatocellular
1
Interventions
Hydroxyurea
3
Bevacizumab
3
pembrolizumab
2
Imatinib Mesylate
2
Everolimus
2
vistusertib
1
vatalanib
1
pasireotide
1
fludarabine phosphate
1
fludarabine
1
arginyllysine
1
antineoplaston AS 2-1
1
antineoplaston A10
1
aldesleukin
1
Whole Body Imaging
1
Verapamil
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiosurgery
1
Proton Therapy
1
Nivolumab
1
Modafinil
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
HDAC-42
1
Fentanyl
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Meningioma
×
ribociclib
×
Clear all
No trials found.